Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Jul-24 9:54 AM View:  | Collard Craig A Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 19-Jul-24 | Option Exercise | 13,797 | -- | -- | 5% 262.79K to 276.59K | |
| 22-Jul-24 9:32 AM View: | Duarte Ira EVP, Chief Financial Officer | AP Pharma Inc. (HRTX) | 19-Jul-24 | Option Exercise | 3,875 | -- | -- | 4% 100.25K to 104.13K | |
| 22-Jul-24 9:44 AM View: | Forbes William P EVP, Chief Development Officer | AP Pharma Inc. (HRTX) | 19-Jul-24 | Option Exercise | 3,875 | -- | -- | 4% 95.37K to 99.25K | |
| 17-Jun-24 2:21 PM View: | Duarte Ira EVP, Chief Financial Officer | AP Pharma Inc. (HRTX) | 16-Jun-24 | Option Exercise | 12,500 | -- | -- | 14% 87.75K to 100.25K | |
| 07-Jun-24 9:34 AM View: | Forbes William P EVP, Chief Development Officer | AP Pharma Inc. (HRTX) | 06-Jun-24 | Option Exercise | 12,500 | -- | -- | 15% 82.87K to 95.37K | |
| 19-Apr-24 5:48 PM View: | Duarte Ira EVP, Chief Financial Officer | AP Pharma Inc. (HRTX) | 19-Apr-24 | Payment of Exercise | 1,122 | $2.64 | $2,962.08 | (1%) 88.87K to 87.75K | |
| 19-Apr-24 5:02 PM View: | Forbes William P EVP, Chief Development Officer | AP Pharma Inc. (HRTX) | 19-Apr-24 | Option Exercise | 3,874 | -- | -- | 5% 79.0K to 82.87K | |
| 19-Apr-24 5:48 PM View: | Duarte Ira EVP, Chief Financial Officer | AP Pharma Inc. (HRTX) | 19-Apr-24 | Option Exercise | 3,874 | -- | -- | 5% 85.0K to 88.87K | |
| 19-Apr-24 4:34 PM View: | Collard Craig A Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 19-Apr-24 | Option Exercise | 13,797 | -- | -- | 6% 249.0K to 262.79K | |
| 05-Apr-24 3:57 PM View: | Collard Craig A Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 03-Apr-24 | Option Exercise | 62,500 | -- | -- | 34% 186.5K to 249.0K | |
| 19-Jan-24 9:02 PM View: | Dissanaike Sharmila Director | AP Pharma Inc. (HRTX) | 19-Jan-24 | Grant | 13,948 | -- | -- | 25% 55.28K to 69.23K | |
| 19-Jan-24 9:04 PM View: | Rodriguez Susan Director | AP Pharma Inc. (HRTX) | 19-Jan-24 | Grant | 13,948 | -- | -- | 25% 55.28K to 69.23K | |
| 19-Jan-24 9:04 PM View: | Morgan Adam Director | AP Pharma Inc. (HRTX) | 19-Jan-24 | Grant | 13,948 | -- | -- | < 1% 7.02M to 7.04M | |
| 19-Jan-24 9:03 PM View: | Johnson Craig A Director | AP Pharma Inc. (HRTX) | 19-Jan-24 | Grant | 13,948 | -- | -- | 27% 51.87K to 65.82K | |
| 19-Jan-24 9:05 PM View: | Christian Waage Director | AP Pharma Inc. (HRTX) | 19-Jan-24 | Grant | 13,948 | -- | -- | 27% 52.23K to 66.18K | |
| 16-Jan-24 5:19 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Jan-24 | Payment of Exercise | 756 | $2.15 | $1,625.40 | (1%) 56.66K to 55.91K | |
| 16-Jan-24 5:19 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Jan-24 | Option Exercise | 1,841 | -- | -- | 3% 54.82K to 56.66K | |
| 21-Nov-23 12:19 PM View: | Forbes William P EVP, Chief Development Officer | AP Pharma Inc. (HRTX) | 17-Nov-23 | Private Purchase | 25,000 | $1.09 | $27,250.00 | 46% 54.0K to 79.0K | |
| 17-Nov-23 12:37 PM View: | Collard Craig A Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 16-Nov-23 | Private Purchase | 150,000 | $0.92 | $137,970.00 | 411% 36.5K to 186.5K | |
| 20-Nov-23 10:07 AM View: | Forbes William P EVP, Chief Development Officer | AP Pharma Inc. (HRTX) | 16-Nov-23 | Private Purchase | 50,000 | $0.94 | $46,995.00 | 1250% 4.0K to 54.0K | |
| 17-Nov-23 12:36 PM View: | Duarte Ira EVP, Chief Financial Officer | AP Pharma Inc. (HRTX) | 16-Nov-23 | Private Purchase | 85,000 | $0.89 | $75,599.00 | 100% 0 to 85.0K | |
| 17-Oct-23 7:57 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Oct-23 | Option Exercise | 2,484 | -- | -- | 5% 53.2K to 55.68K | |
| 17-Oct-23 7:57 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Oct-23 | Payment of Exercise | 860 | $0.72 | $619.20 | (2%) 55.68K to 54.82K | |
| 24-Aug-23 4:09 PM View: | Collard Craig A Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 22-Aug-23 | Payment of Exercise | 692 | $1.65 | $1,141.80 | (2%) 37.19K to 36.5K | |
| 17-Oct-23 7:57 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 25-Jul-23 | Option Exercise | 42,631 | -- | -- | 168% 25.31K to 67.94K | |
| 17-Oct-23 7:57 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 25-Jul-23 | Payment of Exercise | 14,743 | $1.51 | $22,261.90 | (22%) 67.94K to 53.2K | |
| 25-Jul-23 4:22 PM View: | Morgan Adam Director | AP Pharma Inc. (HRTX) | 21-Jul-23 | Private Purchase | 2,486,740 | $1.37 | $3,406,840.00 | 55% 4.54M to 7.02M | |
| 17-Jul-23 5:51 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Jul-23 | Option Exercise | 2,485 | -- | -- | 10% 23.68K to 26.17K | |
| 17-Jul-23 5:51 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Jul-23 | Payment of Exercise | 860 | $1.31 | $1,126.60 | (3%) 26.17K to 25.31K | |
| 17-Jul-23 5:51 PM View: | Szekeres David Leslie EVP, Chief Operating Officer | AP Pharma Inc. (HRTX) | 13-Jul-23 | Payment of Exercise | 2,012 | $1.31 | $2,635.72 | (6%) 35.77K to 33.75K | |
| 17-Jul-23 5:51 PM View: | Szekeres David Leslie EVP, Chief Operating Officer | AP Pharma Inc. (HRTX) | 13-Jul-23 | Option Exercise | 5,814 | -- | -- | 19% 29.95K to 35.77K | |
| 24-May-23 5:04 PM View: | Collard Craig A Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 22-May-23 | Payment of Exercise | 691 | $1.45 | $1,001.95 | (2%) 37.88K to 37.19K | |
| 17-Apr-23 5:27 PM View: | Poyhonen John President & CCO | AP Pharma Inc. (HRTX) | 13-Apr-23 | Option Exercise | 5,814 | -- | -- | 14% 42.85K to 48.66K | |
| 17-Apr-23 5:26 PM View: | Manhard Kimberly EVP, Drug Development | AP Pharma Inc. (HRTX) | 13-Apr-23 | Option Exercise | 5,814 | -- | -- | 24% 23.93K to 29.75K | |
| 17-Apr-23 5:27 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Apr-23 | Payment of Exercise | 860 | $2.88 | $2,476.80 | (4%) 24.55K to 23.68K | |
| 17-Apr-23 5:28 PM View: | Szekeres David Leslie EVP, Chief Operating Officer | AP Pharma Inc. (HRTX) | 13-Apr-23 | Payment of Exercise | 2,012 | $2.88 | $5,794.56 | (6%) 31.96K to 29.95K | |
| 17-Apr-23 5:27 PM View: | Poyhonen John President & CCO | AP Pharma Inc. (HRTX) | 13-Apr-23 | Payment of Exercise | 2,012 | $2.88 | $5,794.56 | (4%) 48.66K to 46.65K | |
| 17-Apr-23 5:28 PM View: | Szekeres David Leslie EVP, Chief Operating Officer | AP Pharma Inc. (HRTX) | 13-Apr-23 | Option Exercise | 5,814 | -- | -- | 22% 26.15K to 31.96K | |
| 17-Apr-23 5:26 PM View: | Manhard Kimberly EVP, Drug Development | AP Pharma Inc. (HRTX) | 13-Apr-23 | Payment of Exercise | 1,417 | $2.88 | $4,080.96 | (5%) 29.75K to 28.33K | |
| 17-Apr-23 5:27 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Apr-23 | Option Exercise | 2,484 | -- | -- | 11% 22.06K to 24.55K | |
| 24-Feb-23 7:20 PM View: | Morgan Adam Director | AP Pharma Inc. (HRTX) | 22-Feb-23 | Grant | 37,879 | -- | -- | < 1% 4.5M to 4.54M | |
| 17-Jan-23 5:34 PM View: | Manhard Kimberly EVP, Drug Development Director | AP Pharma Inc. (HRTX) | 13-Jan-23 | Payment of Exercise | 2,012 | $3.17 | $6,378.04 | (8%) 25.95K to 23.93K | |
| 17-Jan-23 5:36 PM View: | Poyhonen John President & CCO | AP Pharma Inc. (HRTX) | 13-Jan-23 | Payment of Exercise | 2,012 | $3.17 | $6,378.04 | (4%) 44.86K to 42.85K | |
| 17-Jan-23 5:36 PM View: | Quart Barry D Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 13-Jan-23 | Option Exercise | 19,767 | -- | -- | 12% 163.44K to 183.21K | |
| 17-Jan-23 5:37 PM View: | Szekeres David Leslie EVP, Chief Operating Officer | AP Pharma Inc. (HRTX) | 13-Jan-23 | Option Exercise | 5,814 | -- | -- | 26% 22.35K to 28.16K | |
| 17-Jan-23 5:36 PM View: | Quart Barry D Chief Executive Officer Director | AP Pharma Inc. (HRTX) | 13-Jan-23 | Payment of Exercise | 5,219 | $3.17 | $16,544.20 | (3%) 183.21K to 177.99K | |
| 17-Jan-23 5:35 PM View: | Peraza Lisa VP, Chief Accounting Officer | AP Pharma Inc. (HRTX) | 13-Jan-23 | Option Exercise | 2,485 | -- | -- | 12% 20.59K to 23.07K | |
| 17-Jan-23 5:34 PM View: | Manhard Kimberly EVP, Drug Development Director | AP Pharma Inc. (HRTX) | 13-Jan-23 | Option Exercise | 5,814 | -- | -- | 29% 20.13K to 25.95K | |
| 17-Jan-23 5:36 PM View: | Poyhonen John President & CCO | AP Pharma Inc. (HRTX) | 13-Jan-23 | Option Exercise | 5,814 | -- | -- | 15% 39.04K to 44.86K | |
| 17-Jan-23 5:37 PM View: | Szekeres David Leslie EVP, Chief Operating Officer | AP Pharma Inc. (HRTX) | 13-Jan-23 | Payment of Exercise | 2,012 | $3.17 | $6,378.04 | (7%) 28.16K to 26.15K |
